Arizona State Retirement System to Purchase 620 Shares of West Pharmaceutical Services, Inc. (NYSE:WST)

Retirement


Arizona State Retirement System increased its stake in West Pharmaceutical Services, Inc. (NYSE:WST – Get Rating) by 3.0% in the fourth quarter, according to the company’s latest filings with the U.S. Securities and Exchange Commission (SEC). I was. The fund owned his 20,959 shares of the medical device supplier’s stock after acquiring an additional 620 of his shares during the quarter. Arizona State Retirement Plan holdings in West Pharmaceutical Services were worth $4,933,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also changed their WST holdings. Bank of New York Mellon Corp expanded his position in West Pharmaceutical Services stock by 40.5% in the third quarter. Bank of New York Mellon Corp owns 1,742,487 shares of a medical device supplier worth $428,787,000 after purchasing an additional 502,186 shares during this period. AustralianSuper Pty Ltd took a new position worth approximately $77,549,000 in shares of West Pharmaceutical Services in the fourth quarter. Brown Advisory Inc. increased its position in West Pharmaceutical Services stock by 24.1% in the third quarter. After purchasing an additional 236,270 shares during this period, Brown Advisory Inc. now owns 1,216,793 shares of the medical device supplier worth $299,428,000. Durable Capital Partners LP expanded its position in West Pharmaceutical Services equities by 18.7% in the third quarter. Durable Capital Partners LP owns 1,179,447 shares of the medical device supplier valued at $290.238 million after purchasing an additional 185,411 shares during this period. Finally, ProShare Advisors LLC increased its position in West Pharmaceutical Services stock by 35.1% in the fourth quarter. After purchasing an additional 182,459 shares during this period, ProShare Advisors LLC now owns 701,660 shares of the medical device supplier worth $165,136,000. Currently 91.51% of the shares are owned by institutional investors and hedge funds.

Analyst sets new price target

WST has been the subject of several recent analyst reports. Deutsche Bank Aktiengesellschaft raised its price target for West Pharmaceutical Services to $290.00 from his $250.00 in a report on Wednesday, Feb. 22. In his Tuesday, April 11 report, Stephens upgraded West Pharmaceutical Services from an “equally weighted” rating to an “overweighted” rating and raised its price target from $330.00 to $400.00. KeyCorp raised its price target for West Pharmaceutical Services from $315.00 to $375.00, giving the company an “Overweight” rating in its research notes on Friday, February 17. Finally, StockNews.com featured West Pharmaceutical Services in his Thursday, March 16 investigative notes. They put a “Hold” rating on the stock. Four equity research analysts rated the stock with a hold rating and two assigned a buy rating to the company’s stock. According to MarketBeat.com, the company’s current consensus rating is “Hold” with an average target price of $313.00.

West Pharmaceutical Services trading down 0.2%

WST shares opened at $368.46 on Friday. The company has a market capitalization of $27.35 billion, a P/E ratio of 50.61, a PEG ratio of 7.63 and a beta of 1.09. West Pharmaceutical Services, Inc.’s 52-week low is $206.19 and its 52-week high is $376.72. His 50-day simple moving average for this stock is $343.78 and its 200-day simple moving average is $281.65. The company has a debt to equity ratio of 0.07, a quick ratio of 2.79 and a current ratio of 3.62.

West Pharmaceutical Services (NYSE:WST – Get Rating) last released its quarterly earnings data on Thursday, April 27. The medical device supplier reported that his earnings per share for the quarter were $1.98, beating consensus expectations of $1.67 for him by $0.31. The business generated $716.6 million in revenue for the quarter, compared to analyst expectations of $697.28 million. West Pharmaceutical Services had a return on equity of 24.14% and a net profit margin of 19.15%. Business revenue decreased by 0.5% year-on-year. In the same quarter last year, the company made his $2.30 earnings per share. Research analysts expect West Pharmaceutical Services, Inc. to post earnings per share of 7.65 this year.

West Pharmaceutical Services Announces Dividend

The company also recently announced a quarterly dividend payable on Wednesday, August 2nd. Dividends of $0.19 will be issued to shareholders of record on Wednesday, July 26. This represents his $0.76 dividend and his 0.21% dividend yield on an annual basis. The ex-dividend date for this dividend is July 25 (Tuesday). West Pharmaceutical Services’ dividend payout ratio is currently 10.44%.

Insider Trading at West Pharmaceutical Services

In related news, VP Annette F. Favorite sold 13,012 shares in the Monday, May 1st transaction. Her shares were sold at an average price of $365.81 and the total transaction value was her $4,759,919.72. Following the closing of the sale, the Vice President now directly owns 14,877 shares of the company’s stock valued at approximately $5,442,155.37. The sale is disclosed in documents filed with the Securities and Exchange Commission, available at this hyperlink. In another news from West Pharmaceutical Services, director Thomas W. Hofmann sold 1,212 shares of his stock in a transaction that took place on Monday, May 1. The shares were sold at an average price of $365.57, giving him a total of $443,070.84. Following the completion of the sale, the director now owns his 43,616 shares in the company, valued at approximately $15,944,701.12. The transaction was disclosed in documents filed with the SEC and available at this link. VP Annette F. Favorite also sold her 13,012 shares in a transaction that took place on Monday, May 1st. The shares sold at an average price of $365.81, bringing her total to $4,759,919.72. Following the closing of the sale, Vice President now owns 14,877 shares of the Company’s stock valued at approximately $5,442,155.37. Please see here for the disclosure of this sale. In the last three months, the insider has sold 67,744 shares of her company stock worth $22,802,358. 1.13% of the shares are currently owned by company insiders.

West Pharmaceutical Services Company Profile

(get rating)

West Pharmaceutical Services, Inc manufactures and markets pharmaceuticals, biologics, vaccines and consumer healthcare products. It operates through the following business segments: Proprietary Products and Contract Manufacturing Products. The Proprietary Products segment offers proprietary packaging, containment, and drug delivery products, along with analytical laboratory services, to biologics, generics and pharmaceutical customers.

Featured article

Want to know which other hedge funds hold WST? Visit HoldingsChannel.com to get the latest West Pharmaceutical Services, Inc. (NYSE:WST – Get Rating) 13F filings and insider trading.

West Pharmaceutical Services (NYSE:WST) Quarterly Institutional Ownership

This instant news alert was generated by Narrative Science Technology and MarketBeat financial data to provide our readers with the fastest and most accurate reporting. This article was reviewed by MarketBeat’s editorial team prior to publication. Send any questions or comments about this story to contact@marketbeat.com.

Listen to this before considering West Pharmaceutical Services.

MarketBeat tracks Wall Street’s most acclaimed and top performing research analysts and the stocks they recommend to clients every day. MarketBeat has identified five stocks top analysts are quietly whispering to clients to buy now before the broader market catches on…and West Pharmaceutical Services isn’t on the list. bottom.

West Pharmaceutical Services is currently rated as a ‘hold’ among analysts, but top-rated analysts believe these five stocks are better buys.

See 5 stocks here

(Almost) Everything You Need to Know About Covering the EV Market



Source link

Leave a Reply

Your email address will not be published. Required fields are marked *